Search Results
Dec 04, 2025, 08:06 ET NeuroVice Announces PATI Now Available, Launches First FDA-Cleared Device Designed for Seizure Oral Injury Protection and Airway Management at American Epilepsy Society Annual Meeting
added.NeuroVice has attracted significant interest from neurologists, epilepsy specialists, EMS providers, and patient advocates ahead of the AES exhibit."1 in 10 people will have a seizure at some point in their lives. Making PATI commercially available is a pivotal moment in seizure management,"
More news about: NeuroVice
Dec 03, 2025, 07:30 ET ADC Therapeutics Announces Updated Data from LOTIS-7 Phase 1b Clinical Trial of ZYNLONTA® in Combination with Bispecific Antibody Supporting Potential Best-in-Class Regimen in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma
achieving CR remain in CR as of the data cutoff; the 5 patients who did not remain in CR included 2 patients with progressive disease, 2 patients with Grade 5 AEs which occurred during CR, and one censored patientStrong efficacy in both the relapsed and primary refractory populations across both
More news about: ADC Therapeutics SA
Dec 03, 2025, 07:00 ET GRIN Therapeutics to Present on Global Phase 3 Beeline Clinical Trial of Radiprodil at American Epilepsy Society Annual Meeting
development of novel rating scales for GRIN-related neurodevelopmental disorder (GRIN-NDD) in a poster presentation at the American Epilepsy Society (AES) Annual Meeting being held December 5-9, 2025, in Atlanta, GA. These include the newly developed Clinical Global Impression of Severity (CGI-S) and Change
More news about: GRIN Therapeutics Inc.
Dec 02, 2025, 08:15 ET AbbVie to Feature New Data at ASH 2025 Showcasing Continued Advances Across Novel Treatment Modalities in Multiple Blood Cancers
[98.0%] 0.53-1.32).3 The 3-year PFS for VO, I and IV arms were 81.1%, 81.0% and 79.4% respectively.3The most frequent adverse events (AEs) were infections and infestations (VO: 76.3%, VI: 80.2%, I: 79.9%), gastrointestinal disorders (VO: 59.7%, VI: 74.3%, I: 63.4%), and blood and lymphatic
More news about: AbbVie Inc.
Dec 02, 2025, 02:27 ET Lundbeck to present comprehensive new bexicaserin dataset in patients with rare childhood-onset epilepsies, at American Epilepsy Society (AES) Annual Meeting
New data to be presented at the 2025 AES Annual Meeting indicate sustained reductions in seizure frequency as early as two weeks after treatment initiation with bexicaserin1Bexicaserin is an investigational compound in development for the treatment of seizures
More news about: H. Lundbeck A/S
Dec 02, 2025, 02:25 ET Lundbeck to present comprehensive new bexicaserin dataset in patients with rare childhood-onset epilepsies, at American Epilepsy Society (AES) Annual Meeting
New data to be presented at the 2025 AES Annual Meeting indicate sustained reductions in seizure frequency as early as two weeks after treatment initiation with bexicaserin1Bexicaserin is an investigational compound in development for the treatment of seizures
More news about: H. Lundbeck A/S
Dec 01, 2025, 09:00 ET Biocodex To Present New Data at the American Epilepsy Society (AES) 2025 Annual Meeting
previewed what providers can expect to see from Biocodex at AES this year."Biocodex USA is thrilled to be attending AES this year. We are dedicated to bringing new data to our healthcare providers and researchers; but most importantly, our AES attendance will highlight our partnerships with thought
More news about: Biocodex, Inc.
Dec 01, 2025, 09:00 ET Annualized Severe COPD Exacerbation Rate Reduced by Over 40%: Mabwell Announces Phase IIa Results for Innovative Anti-ST2 Antibody 9MW1911
of <300/μL. Compared to placebo (N=20), 9MW1911 was safe and well-tolerated across all dose groups, with the overall incidence of adverse events (AEs) being similar to the placebo group (70% vs. 85%). Immunogenicity was negative in all subjects, and no new safety risk signals were identified. Pharmacokinetic
More news about: Mabwell
Dec 01, 2025, 08:15 ET LGS Foundation Accelerates Lennox-Gastaut Syndrome Research, Invites Researchers, HCPs & Industry to Join the Momentum
American Epilepsy Society's (AES) Annual Meeting in Atlanta, GA this weekend.
More news about: Lennox-Gastaut Syndrome (LGS) Foundation
Nov 28, 2025, 04:06 ET China's First Domestic IL-23p19 Monoclonal Antibody: Innovent's PECONDLE® (Picankibart Injection) Received NMPA Approval
in special areas (scalp, nail, palmoplantar and perineal); The overall safety of picankibart was favorable. The most common adverse events (AEs) was upper respiratory tract infection, which was consistent with the safety profile of other IL-23p19 agents. No new safety signals were identified.
More news about: Innovent Biologics
Nov 28, 2025, 00:13 ET The Annals of Oncology Publishes Results of Phase II Study of Sacituzumab Tirumotecan Monotherapy for Urothelial Carcinoma
sac-TMT was manageable, the most frequent grade 3 or 4 treatment-related adverse events (AEs) (≥5%) were hematologic toxicities and stomatitis, with no febrile neutropenia events or grade 5 treatment-related AEs.Professor Ye Dingwei, Vice President of Fudan University Shanghai Cancer Center, stated,
More news about: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Nov 27, 2025, 10:47 ET Internet of Behaviors Market Surges to USD 14.3 Billion by 2033, Propelled by 26.5% CAGR - Verified Market Reports®
Deployment Type (Cloud, On-Premises), By Enterprise Type (Large Enterprises, Small & Medium Enterprises), By Level (Advanced Electronic Signatures (AES), Qualified Electronic Signatures (QES)),By Industry (BFSI, IT & Telecom), By Component (Software, Hardware), By Geographic Scope And Forecast
More news about: Verified Market Reports
Nov 26, 2025, 20:00 ET SSSTC, 16TB 기업용 ER4 시리즈 SATA SSD 출시… 랜덤 읽기•쓰기 성능 '동급 최고 수준'
IOPS 랜덤 읽기 성능을 제공해 높은 동시 작업 환경에서의 처리 능력을 개선한다. 이는 OLTP, AI 추론, 클라우드 컴퓨팅, 빅데이터 분석 등 저지연 워크로드에서 중요한 이점을 제공한다.또한 ER4 시리즈는 엔드 투 엔드 데이터 보호, True PLP 전원 차단 보호, 보안 삭제 기능, AES-256 암호화(TCG Enterprise 옵션) 등 다양한 기업용 데이터 보안 기능을 지원해 데이터 전송 및 저장 과정의 무결성을 보장한다.신뢰성 측면에서는 300만 시간 MTBF, 10⁻¹⁷ UBER, 5년 보증을 제공해 기업용 환경에서 요구되는 장기
More news about: FireNews
Nov 26, 2025, 10:00 ET UPSHER-SMITH STRENGTHENS CONNECTIONS WITH THE EPILEPSY COMMUNITY THROUGH AWARENESS, EDUCATION, AND SUPPORT
support available to affected families.Advancing Clinical Knowledge of Infantile Spasms at the AES Annual MeetingUpsher-Smith will also participate in the American Epilepsy Society (AES) Annual Meeting, held December 5–9, 2025, in Atlanta, GA. Company representatives will be available
More news about: Upsher-Smith Laboratories, LLC
Nov 25, 2025, 05:28 ET Comulytic Launches Groundbreaking Dual-Scenario AI Recording Device, Redefining Office and Client Management with Unprecedented Performance
calls, video meetings, multi-participant discussions, and one-on-one conversations.On data security, the AI partner uses AWS cloud storage and AES encryption technology to help safeguard user information, providing users with complete data control rights and strict usage regulations. According to
More news about: Comulytic
Nov 21, 2025, 08:04 ET SK Life Science, Inc. to Present 10 Posters with New Cenobamate Data, Including a Late-Breaker, at the 2025 American Epilepsy Society (AES) Annual Meeting
subsidiary of SK Biopharmaceuticals Co., Ltd., will present new data on cenobamate, an anti-seizure medication, at the 2025 American Epilepsy Society (AES) Annual Meeting in Atlanta, Georgia, December 5-9, 2025.
More news about: SK Life Science, Inc.
Nov 19, 2025, 09:50 ET DeskIn: Redefining Remote Desktop -- The Essential Lifestyle App for the AI Generation
data. International Certifications & Encryption Standards: Utilizes bank-grade AES-256 encryption and is certified under ISO 27001 for information security management and ISO 9001 for quality management, meeting globally recognized
More news about: Zuler Technology PTE. LTD.
Nov 19, 2025, 08:00 ET Bracco Delivers 3 Million VUEWAY® Doses, Meeting Patient Demand for Lower-Dose MRI Contrast
databases, clinical and epidemiological studies, and administrative claims data from health insurers.7 Adverse events (AEs) were classified as "serious" or "non-serious" by qualified pharmacovigilance personnel, in accordance with international regulatory definitions. All
More news about: Bracco Group
Nov 19, 2025, 07:12 ET PAN GLOBAL OBTIENT 1,14 G/T D'OR SUR 26 METRES PRÈS DE LA SURFACE SUR LA CIBLE CANADA HONDA DU PROJET ESCACENA, DANS LE SUD DE L'ESPAGNE
(Au-ICP22). L'analyse multiéléments a été réalisée à l'aide d'un digest à 4 acides avec finition ICP-AES (ME-ICP61). Les échantillons à teneur excessive ont été analysés par digestion quadriacide avec finition ICP-AES pour les métaux de base (OG62), et par pyroanalyse avec finition gravimétrique pour l'or (Au-GRA22).
More news about: Pan Global Resources Inc.
Nov 19, 2025, 02:55 ET Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-1 Trial of VK2735
signs of plateau. VK2735 also demonstrated encouraging safety and tolerability in the VENTURE study, with the majority of observed adverse events (AEs) being reported as mild or moderate. Treatment and study discontinuation rates among VK2735 cohorts were well-balanced compared with placebo.
More news about: Viking Therapeutics, Inc.
Nov 18, 2025, 10:30 ET Microplastic Analysis Market worth $383.1 million by 2030 with 7.5% CAGR | MarketsandMarkets™
high-performance liquid chromatography (HPLC), gas chromatography (GC) and GC-MS systems, ICP-MS and atomic absorption platforms, LC-MS systems, MP-AES instruments, automated sample handling systems, dissolution testing equipment, vacuum technologies, and other precision analytical tools. These platforms
More news about: MarketsandMarkets
Nov 18, 2025, 00:30 ET PAN GLOBAL BEPROBT 1,14 G/T GOLD ÜBER 26 METER NAHE DER OBERFLÄCHE IM ZIELGEBIET CANADA HONDA, ESCACENA-PROJEKT, SÜDSPANIEN
50-g-Brandprobe mit ICP-Abschluss (Au-ICP22). Die Multielementanalyse wurde mit einem 4-Säuren-Aufschluss mit ICP-AES-Abschluss (ME-ICP61) durchgeführt. Übergradproben wurden mittels 4-Säure-Aufschluss mit ICP-AES-Finish für Basismetalle (OG62) und mittels Feuerprobe mit Gravitationsfinish für Gold (Au-GRA22) analysiert.
More news about: Pan Global Resources Inc.
Nov 18, 2025, 00:30 ET PAN GLOBAL SAMPLES 1.14 G/T GOLD OVER 26 METERS FROM NEAR SURFACE AT CANADA HONDA TARGET, ESCACENA PROJECT, SOUTHERN SPAIN
Fire assay with ICP finish (Au-ICP22). Multi element analysis was undertaken using a 4-acid digest with ICP-AES finish (ME-ICP61). Over-grade samples were analyzed using 4-acid digest with ICP-AES finish for base metals (OG62), and Fire Assay with Gravity Finish for gold (Au-GRA22). Certified reference
More news about: Pan Global Resources Inc.
Nov 18, 2025, 00:30 ET PAN GLOBAL SAMPLES 1.14 G/T GOLD OVER 26 METERS FROM NEAR SURFACE AT CANADA HONDA TARGET, ESCACENA PROJECT, SOUTHERN SPAIN
Fire assay with ICP finish (Au-ICP22). Multi element analysis was undertaken using a 4-acid digest with ICP-AES finish (ME-ICP61). Over-grade samples were analyzed using 4-acid digest with ICP-AES finish for base metals (OG62), and Fire Assay with Gravity Finish for gold (Au-GRA22). Certified reference
More news about: Pan Global Resources Inc.
Nov 18, 2025, 00:30 ET PAN GLOBAL MUESTREA 26 METROS CON 1,14 G/T DE ORO CERCA DE LA SUPERFICIE EN EL OBJETIVO DE CAÑADA HONDA
(Au-ICP22). El análisis multielemento se realizó mediante digestión con 4 ácidos con acabado ICP-AES (ME-ICP61). Las muestras con ley superior se analizaron mediante digestión con 4 ácidos con acabado ICP-AES para metales básicos (OG62) y ensayo al fuego con acabado por gravedad para oro (Au-GRA22). Se
More news about: Pan Global Resources Inc.